Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 8,242 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Humans Clear all
Completed Phase 2 Interventional Results available

Recombinant Human Prolactin for Lactation Induction

NCT00181610
View directory record Official record
Conditions
Lactation
Interventions
Recombinant Human Prolactin, Recombinant human prolactin, Normal Saline
Drug · Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 3, 2018 · Synced Oct 25, 2026, 4:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

NCT00875979
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Trastuzumab emtansine [Kadcyla] 3.0 mg/kg, Trastuzumab emtansine [Kadcyla] 3.6 mg/kg, Pertuzumab 420 mg
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
10
States / cities
Boca Raton, Florida • Deerfield Beach, Florida • Maywood, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2013 · Synced Oct 25, 2026, 4:33 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

iTBS Methods and Motor Cortex Excitability

NCT03584438
View directory record Official record
Conditions
Motor Activity
Interventions
Real iTBS, Sham iTBS
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 25, 2026, 4:33 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

NCT02214225
View directory record Official record
Conditions
Influenza, Human
Interventions
Quadrivalent Influenza Vaccine (QIV), Trivalent Influenza Vaccine (TIV-1), Trivalent Influenza Vaccine (TIV-2)
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
3,484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
33
States / cities
Huntsville, Alabama • Los Angeles, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 25, 2026, 4:33 AM EDT
Completed No phase listed Observational

Epidemiological Study in Children and Adolescents With Chronic Hepatitis B

NCT01163240
View directory record Official record
Conditions
Liver Diseases, Hepatitis, Chronic, Hepatitis, Viral, Human, Hepatitis, Virus Diseases, Digestive System Diseases, Hepatitis B, Chronic, Hepatitis B, DNA Virus Infections
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
1,640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
5
States / cities
Aurora, Colorado • Gainesville, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Oct 25, 2026, 4:33 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Modulation of Human Myocardial Metabolism by GLP-1 Dose Response

NCT01607450
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Healthy
Interventions
GLP-1 Low Dose, GLP-1 Mid-Range Dose, GLP-1 High Dose, Saline
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 25, 2026, 4:33 AM EDT
Active, not recruiting Phase 3 Interventional

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)

NCT07246590
View directory record Official record
Conditions
Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Interventions
VP-102, Vehicle
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
2 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
17
States / cities
Miami, Florida • Saint Augustine, Florida • Meridian, Idaho + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 25, 2026, 4:33 AM EDT
Completed Phase 3 Interventional Results available

REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

NCT03185013
View directory record Official record
Conditions
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
Interventions
VGX-3100, Placebo, Electroporation (EP)
Biological · Device
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
22
States / cities
Mesa, Arizona • Scottsdale, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 25, 2026, 4:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Work Hour Reductions, Medical Errors, and Intern Well-Being at Providence St. Vincent Medical Center Intensive Care Unit

NCT00996320
View directory record Official record
Conditions
Sleep Deprivation, Depression
Interventions
Reduced work hour schedule
Other
Lead sponsor
Providence Health & Services
Other
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 16, 2009 · Synced Oct 25, 2026, 4:33 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

NCT04707248
View directory record Official record
Conditions
Renal Cell Carcinoma, Ovarian Tumor
Interventions
DS-6000a
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
6
States / cities
Tucson, Arizona • Denver, Colorado • Lake Mary, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 25, 2026, 4:33 AM EDT
Completed No phase listed Observational

Observational Trial of Hepatitis C Virus Infected Patients on Calcineurin Inhibitors

NCT00819026
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Oct 25, 2026, 4:33 AM EDT
Completed Not applicable Interventional

The Effects of Anti-HIV Therapy on the Immune Systems of Children and Young Adults Infected With HIV

NCT00004735
View directory record Official record
Conditions
HIV Infections
Interventions
Tetanus toxoid, Hepatitis A Vaccine (Inactivated)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 24 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
25
States / cities
Birmingham, Alabama • Alhambra, California • Long Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Oct 25, 2026, 4:33 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Spinal Cord Stimulation for Functional Recovery in Humans With Tetraplegia

NCT05157282
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
TESS, Training, Motor Task, sham-TESS
Device · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 25, 2026, 4:33 AM EDT
Not yet recruiting Phase 4 Interventional

AI-Powered Hepatitis C Single-Encounter Test-and-Treat

NCT07793643
View directory record Official record
Conditions
HEPATITIS C (HCV)
Interventions
Epclusa (sofosbuvir and velpatasvir)
Drug
Lead sponsor
Patrick Grace
Other
Eligibility
22 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 25, 2026, 4:33 AM EDT
Completed Phase 3 Interventional Results available

Use of NPSP558 in the Treatment of Hypoparathyroidism

NCT00732615
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
Placebo, NPSP558
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 85 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
19
States / cities
Scottsdale, Arizona • Lakewood, California • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 25, 2026, 4:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Triglyceride Effects on Blood Flow in the Human Brain

NCT05218018
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Lipid drink
Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
55 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 25, 2026, 4:33 AM EDT
Completed Phase 1 Interventional

First-in-human Study of Oral TP-0184 in Patients With Advanced Solid Tumors

NCT03429218
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
TP-0184
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Kansas City, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 25, 2026, 4:33 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3

NCT01616524
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Pegylated interferon lambda (pegIFNλ), Pegylated interferon alfa-2a (pegIFNα-2a), Ribavirin, Daclatasvir, Placebo matching Daclatasvir
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
18
States / cities
Phoenix, Arizona • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 25, 2026, 4:33 AM EDT
Completed No phase listed Observational Results available

Growth and Microbiome Development in Very Low Birth Weight Infants Fed Primarily Mother's Own Milk vs. Donor Human Milk

NCT02573779
View directory record Official record
Conditions
Infant, Very Low Birth Weight
Interventions
Observational - no intervention
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 3 Days
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Oct 25, 2026, 4:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Oocyte Cryopreservation: The Impact of Cryopreservation on the Meiotic Spindle and Mitochondria of Human Oocytes.

NCT00716118
View directory record Official record
Conditions
Infertility
Interventions
Not listed
Lead sponsor
West Coast Fertility Centers
Other
Eligibility
21 Years to 37 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Fountain Valley, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2011 · Synced Oct 25, 2026, 4:33 AM EDT
Completed Not applicable Interventional Results available

CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeS

NCT02402218
View directory record Official record
Conditions
Hepatitis C Virus Infection, Response to Therapy of, Human Immunodeficiency Virus
Interventions
Usual care plus peer-mentors, Usual care plus incentives, Usual Care
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Oct 25, 2026, 4:33 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Pomegranate Products for Prevention of Common Cold

NCT00617318
View directory record Official record
Conditions
Influenza, Common Cold, Cough, Headache, Fever
Interventions
Pomegranate, Placebo
Dietary Supplement
Lead sponsor
Texas Heart Institute
Other
Eligibility
21 Years to 49 Years
Enrollment
461 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 18, 2008 · Synced Oct 25, 2026, 4:33 AM EDT
Completed No phase listed Observational

Eliminating Hepatitis C Virus

NCT03401697
View directory record Official record
Conditions
Hepatitis C, HIV, Type2 Diabetes
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
52 participants
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 25, 2026, 4:33 AM EDT
Recruiting Phase 1 Interventional

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

NCT05142189
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
BNT116, Cemiplimab, Docetaxel, Carboplatin, Paclitaxel, BNT316, anti-B7-H3 antibody conjugated to topoisomerase I inhibitor, anti-HER3 antibody conjugated to topoisomerase I inhibitor, Bispecific antibody for PD-L1 and VEGF-A, Osimertinib, ALK-inhibitor or RET-inhibitor
Biological · Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
6
States / cities
Lexington, Kentucky • Louisville, Kentucky • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 25, 2026, 4:33 AM EDT